CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference
Mar 28, 2018, 09:17 ET
MONMOUTH JUNCTION, N.J., March 28, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ : CTSO ), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports on the success of its 5th International CytoSorb Users Meeting and a record turnout during its Satellite Research Symposium at the 38th International Symposium of Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium last week.
ISICEM is one the largest and most influential critical care conferences in the world which takes place in Brussels, Belgium every spring. The conference was very well-attended, with approximately 6,200 participants this year, and an impressive speaker list of hundreds of leading international key opinion leaders (KOL) in intensive care and emergency medicine.
Just prior to the meeting, CytoSorbents held its 5th International CytoSorb Users Meeting, relocating to the larger ISICEM conference center from the Hotel Marivaux in years past, to accommodate nearly 150 participants from the growing global CytoSorb community, including physicians, partners, and distributors. The goal of the meeting was to invite CytoSorb users to share their treatment experiences and research with the group, fostering healthy discussion about how to best optimize treatment in a wide range of different applications. Professor Jean-Louis Vincent, one of the top worldwide KOLs in critical care and the organizer of the ISICEM conference, gave the opening lecture on "The Role of Personalized Medicine on the ICU", supporting CytoSorbents' strategy of conducting smaller, but targeted studies in well-defined patient populations. In all, twenty-three speakers and session chairs from ten countries contributed to the meeting, including many of the pioneers of the therapy. One common theme throughout the majority of the clinical presentations was the valuable role that CytoSorb plays in helping to restore hemodynamic stability in these critically-ill patients. In addition, exciting new mechanistic data highlight the ability of CytoSorb to improve microcirculation and tissue oxygenation, a key physiologic deficit in septic shock, as well as to modulate the immune system on both a cellular and molecular level. The complete agenda can be found here.
CytoSorbents also had its most successful Satellite Research Symposium at ISICEM ever, with approximately 600 people in the auditorium, with presentations that summarized the current positive clinical experience with CytoSorb, reiterated the excellent safety profile of the therapy, and highlighted promising new applications such as extracorporeal membrane oxygenation (ECMO) after cardiac arrest. The agenda can be found here. In addition, many physicians in the CytoSorb community reported that CytoSorb was favorably mentioned in many lectures of the main program of the general ISICEM conference as a safe, feasible, and increasingly established adjunctive therapy in critical care. This represented a significant change from years past.
The record attendance at the CytoSorb Research Symposium and Users meeting, the frequent mentions of CytoSorb by speakers in the main sessions, multiple accepted poster presentations, and the excellent visibility and traffic at the Company's exhibit booth with many important KOLs expressing their intention to start routine treatment or strong interest to collaborate in clinical and scientific studies, points to the broad and growing international awareness, interest, and usage of the therapy.
New pictures of these events can be found on the CytoSorbents Facebook page.
About ISICEM
The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine. This annual conference was started in 1980 and has become established as one of the largest in its field, now attracting more than 6,000 participants from countries worldwide. The objectives of this four-day symposium are to provide participants with an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses, and other health professionals with an interest in critical care or emergency medicine.
About CytoSorbents Corporation (NASDAQ : CTSO )
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 45 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents recently initiated its pivotal REFRESH (REduction in FREe Hemoglobin) 2 trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury. CytoSorb® has been used in more than 35,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $22 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
CytoSorbents Contact:
Amy Vogel
Investor Relations
732-398-5394
avogel@cytosorbents.com
Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors
917-749-1494
jeremy@lifesciadvisors.com
Public Relations Contact:
Joshua Berkman
Rubenstein Public Relations
212-805-3055
jberkman@rubensteinpr.com
SOURCE CytoSorbents Corporation
Share this article